Prescient’s PTX-100 granted FDA’s Orphan Drug Designation for all T-cell lymphomas
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders...
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...
Prescient Therapeutics (ASX: PTX) featured in the ‘Investor Guide for Health & Biotech’ by The...
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR...
There are many foundations and charities which aim to tackle health conditions through funding medical...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class,...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.